- Idenix's hepatitis program for two investigational agents placed on clinical hold by FDA, shares plummet
- FDA to allow continued availability of Shire's ProAmatine, generic formulations, reversing earlier decision to withdraw products
- FDA advisory panel recommends approval of Forest Labs' IV antimicrobial ceftaroline for treating pneumonia, complicated skin and skin structure infections
- FDA approves expanded indications for Merck's Saphris antipsychotic
- FDA reviewers support efficacy of Forest Labs' IV antimicrobial ceftaroline for treating pneumonia, complicated skin and skin structure infections
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
San Antonio Breast Cancer Symposium
30th Annual SABCS
December 12-16, 2007San Antonio, TexasCompletion axillary dissection may not be required after positive sentinel node biopsy
Although completion axillary dissection following a positive sentinel biopsy is helpful in prognosis and treatment planning, it may not be required in patients with small tumors and in the absence of lymphovascular invasion, according to data from the NSABP B-32 study.
The researchers explained that a positive sentinel ...[more] 
Denosumab increases BMD in women with breast cancer receiving AI therapy, findings indicate
Twice-yearly administration of denosumab consistently increased bone mineral density (BMD) during 24 months of treatment in women with nonmetastatic breast cancer who had low bone mass and were receiving adjuvant aromatase inhibitors (AI), data from the Phase III HALT Breast Cancer 135 study showed.
Although adjuvant ...[more]
Continuation of tamoxifen beyond standard 5 years reduces breast cancer recurrence, preliminary data show
Continuation of tamoxifen beyond the current standard duration of 5 years reduces recurrence over the next few years, according to an early analysis of the latest preliminary data from the ATLAS study.
The researchers explained that despite data showing that 5 years of tamoxifen therapy substantially reduces the annual ...[more]
Micrometastatic deposits in sentinel nodes may play role in treatment decisions, data show
Micrometastatic deposits in the sentinel nodes may help to eventually define which patients should receive maximum adjuvant therapy (medical or surgical) and which patients could avoid additional therapy, according to results from a prospective study.
One of the most significant prognostic factors for patients with breast ...[more]
Anastrozole appears superior to tamoxifen in reducing risk of recurrence in patients with early breast cancer, data show
Anastrozole significantly reduces the risk of recurrence as compared with tamoxifen citrate in postmenopausal women with hormone receptor (HR)-positive breast cancer, according to long-term follow-up data from the ATAC study. However, the data also revealed that anastrozole, an aromatase inhibitor (AI), is associated with a higher ...[more]
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
- PSA screening controversy increases with release of mortality studies with conflicting results, modest benefits
- Men with biopsy Gleason score 7, tertiary grade 5 disease face similar risk of PSA recurrence as men with higher Gleason score disease, study data suggest
- Researchers evaluate predictors of re-excision, residual disease in women with close, positive margins following partial mastectomy
- Addition of both androgen suppression therapy, external-beam radiation to brachytherapy decreases prostate cancer-specific mortality in men with high-risk disease, study shows
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
- Radiation therapy for prostate cancer raises bladder, rectal cancer risk, study indicates
- ACE inhibitors, ARBs may reduce risk of nonmelanoma skin cancer in high-risk patients, researchers report
- Dietary intervention appears useful in men with prostate cancer
- Many survivors of childhood cancer do not get cancer-focused aftercare, study shows
